Authors

  • Mark Belsey
  • Alex K Pavlou

DOI:

https://doi.org/10.5912/jcb127

Keywords:

DNA, RNA, antisense, aptamer, gene therapy, RNAi

Abstract

The DNA/RNA market is currently at an early stage of development, with only two marketed products that together generated an estimated US$30m in 2004. The launch of Pfizer/Eyetech's ophthalmological aptamer Macugen (pegaptanib) is set to help power market growth to US$1.2bn by 2010. Of the 229 active DNA/RNA programmes identified by Datamonitor, oncology currently dominates the therapeutic focus, while antisense and gene therapies dominate the technological focus.

Downloads